, /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible ...

Group 1 - The article discusses the initial coverage of 10x Genomics (NASDAQ: TXG) with a pessimistic outlook due to expected persistent losses through at least 2028 despite a strong balance sheet [1] - The analyst highlights a focus on finding underappreciated companies that can return value to investors, indicating a contrarian investment philosophy [1] Group 2 - There are no stock, option, or similar derivative positions held by the analyst in any mentioned companies, nor plans to initiate such positions within the next 72 hours [2] - The article expresses the author's own opinions without receiving compensation from any company mentioned [2]

Summary of Analyst Ratings Changes Core Viewpoint - Top Wall Street analysts have revised their outlook on several companies, providing new ratings and price targets for their stocks [1]. Company-Specific Summaries - **Eaton Corporation plc (ETN)**: Daiwa Capital analyst Jairam Nathan initiated coverage with an Outperform rating and a price target of $390, while shares closed at $362.25 [6]. - **Synaptics Incorporated (SYNA)**: Deutsche Bank analyst Ross Seymore initiated coverage with a Buy rating and a price target of $85, with shares closing at $69.10 [6]. - **Celsius Holdings, Inc. (CELH)**: Goldman Sachs analyst Bonnie Herzog initiated coverage with a Buy rating and a price target of $72, while shares closed at $56.22 [6]. - **Solventum Corporation (SOLV)**: Jefferies analyst Michael Toomey initiated coverage with a Hold rating and a price target of $80, with shares closing at $71.22 [6]. - **10x Genomics, Inc. (TXG)**: Piper Sandler analyst David Westenberg initiated coverage with a Neutral rating and a price target of $15, while shares closed at $12.59 [6].

Core Insights - The past nine months have been eventful for 10x Genomics, marked by significant changes in the macro environment and various policy headwinds impacting end markets [1] Company Performance - The company started the year with strong momentum, but faced numerous challenges throughout the year [1] - The CEO expressed pride in the team's execution despite the ongoing difficulties and challenges encountered [1]

Core Insights - The past nine months have been eventful for 10x Genomics, marked by significant changes in the macro environment and various policy headwinds impacting end markets [1] Company Performance - The company started the year with strong momentum, but faced numerous challenges throughout the year [1] - The CEO expressed pride in the team's execution despite the ongoing difficulties and challenges encountered [1]

Summary of 10x Genomics Conference Call Company Overview - **Company**: 10x Genomics - **Event**: Morgan Stanley Global Healthcare Conference - **Speaker**: Serge Saxonov, Co-founder and CEO Key Points Industry Context - The healthcare and life sciences tools industry has faced various macroeconomic challenges over the past year, impacting customer sentiment and spending patterns [3][4][6] - Academic customers in the U.S. are cautiously optimistic but remain uncertain about future funding, particularly from NIH [6][8][9] - The biopharma sector is experiencing a recession, with biotech companies struggling for funding, while larger pharma companies are cautious due to uncertainties in pricing and policy [12][13][14] Company Achievements - 10x Genomics completed a commercial restructuring and made significant progress in product development, including the upcoming launch of the Chromium Single Cell Gene Expression Flex V2 [5][19] - The company has maintained a strong balance sheet and focused on cost management, positioning itself to navigate current challenges and emerge stronger [5] Market Sentiment - Customer sentiment in the academic market has not significantly improved; spending remains cautious due to uncertainties around funding and budget clarity [7][8] - In Europe and Asia, there is increased scrutiny on capital equipment purchases, with departments questioning the necessity of new instruments [9][10] Product Development and Launches - The Chromium Single Cell Gene Expression Flex V2 is expected to launch later this year, with positive feedback from early access customers [19][20] - The transition from NextGen to GenX consumables is ongoing, with most customers expected to switch by early next year [22][24] Market Dynamics - There is a preference for consumable purchases over large capital equipment in the current environment [16] - Both single cell and spatial modalities are seeing interest, with spatial tools emerging as a promising area for growth [16][17] Competitive Landscape - 10x Genomics maintains a strong competitive position in the single cell market, with superior data quality and customer support compared to competitors [35][36] - The company is aware of emerging technologies like the STANT method but believes its products offer deeper insights and better performance [38][39] Strategic Acquisitions - The acquisition of Scale Biosciences is aimed at enhancing single cell analysis capabilities by integrating innovative technologies [30][31] Future Outlook - The company is optimistic about the long-term growth potential in the single cell market, driven by lower price points and increased adoption [26][27] - 10x Genomics is well-positioned to capitalize on the growing demand for single cell and spatial analysis in biological research and drug discovery [58][59] Closing Remarks - The CEO emphasized the strength of the company's fundamentals and its strategic position in the market, highlighting the importance of single cell and spatial approaches in future biological research [57][58]

Core Insights - CLISEQ Ltd. has announced a collaboration with 10x Genomics and the Weizmann Institute to launch the PERIBLOOD clinical trial, which aims to evaluate single cell RNA sequencing from blood as a non-invasive method for diagnosing blood disorders [1][2][3] - The trial will enroll over 1,500 participants globally and compare single cell profiles from peripheral blood with traditional bone marrow aspiration results to assess the viability of this new diagnostic approach [1][2][3] Group 1: Clinical Trial Details - The PERIBLOOD trial is a three-year study sponsored by the Weizmann Institute, with plans to enroll participants from North America, Europe, Asia, Latin America, and Israel [1] - Participants will include individuals with low and high blood counts, as well as healthy volunteers, to evaluate the effectiveness of the new diagnostic method for Myelodysplastic Syndromes (MDS) and other hematological disorders [1][2] Group 2: Technology and Methodology - The trial utilizes a novel technology developed by Professors Liran Shlush and Amos Tanay, which has shown the ability to accurately diagnose MDS from peripheral blood [2][5] - 10x Genomics' Chromium GEM-X Single Cell technology will be employed to analyze thousands of individual cells in each blood sample, generating detailed molecular profiles that may reveal insights missed by traditional testing methods [3][4] Group 3: Implications and Future Directions - If successful, the study could lead to a significant shift in how blood disorders are diagnosed, making the process less invasive and more accessible [4][5] - The findings from this trial may inform future diagnostic product development in hematology, enhancing patient experience and clinical decision-making [4][5]

Core Insights - 10x Genomics has launched Xenium Protein, the first fully integrated spatial multiomic assay that allows simultaneous RNA and protein detection in the same cell and tissue section, enhancing biological insights without the need for data integration from multiple technologies [1][2] Group 1: Product Features - Xenium Protein expands the Xenium Spatial platform with ready-to-use protein subpanels that work seamlessly with RNA panels, focusing on proteins involved in cell growth, signaling, and immune response, which are crucial for studying cancer and immunology [2][4] - The new assay simplifies experimental design by reducing the need for separate workflows or sample sections, allowing researchers to capture both RNA and protein data in a single automated run, thus accelerating the pace of discoveries [3][4] Group 2: Industry Impact - Integrated multiomic analysis is essential for advancing the understanding of complex diseases and accelerating therapeutic discovery, as highlighted by industry experts [2][4] - Early access customers are already utilizing Xenium Protein for various research applications, from early discovery to large-scale atlasing efforts, indicating its broad applicability in the field [3]

Core Insights - The article emphasizes the importance of efficiency levels in assessing a company's potential for profitability, suggesting that higher efficiency correlates with better price performance [1] Efficiency Ratios - Receivables Turnover: This ratio measures a company's ability to collect debts and extend credit, with a higher ratio indicating better performance [2] - Asset Utilization: This ratio reflects a company's efficiency in converting assets into sales, with higher values suggesting better efficiency [3] - Inventory Turnover: This ratio indicates how well a company manages its inventory relative to its cost of goods sold, with higher values signaling effective inventory management [4] - Operating Margin: This ratio assesses a company's control over operating expenses, with higher values indicating more efficient expense management [5] Screening Criteria - The screening process included a favorable Zacks Rank (1 Strong Buy) alongside the efficiency ratios, narrowing down over 7,906 stocks to 15 strong candidates [6][9] Top Stocks Identified - The top five stocks identified for their efficiency include: - Tsakos Energy Navigation Limited (TEN) with an average four-quarter earnings surprise of 46.7% [10] - 10x Genomics, Inc. (TXG) also with an average four-quarter earnings surprise of 46.7% [11] - Pan American Silver Corp. (PAAS) with an average four-quarter earnings surprise of 45.2% [12] - Wolverine World Wide, Inc. (WWW) with an average four-quarter earnings surprise of 39.1% [13] - Interface (TILE) with an average four-quarter earnings surprise of 33.5% [14]

Core Insights - 10x Genomics reported revenue of $172.91 million for the quarter ended June 2025, reflecting a year-over-year increase of 12.9% and surpassing the Zacks Consensus Estimate of $139.44 million by 24% [1] - The company achieved an EPS of $0.28, a significant improvement from -$0.32 in the same quarter last year, resulting in an EPS surprise of 180% compared to the consensus estimate of -$0.35 [1] Revenue Breakdown - Consumables revenue reached $122.19 million, slightly above the average estimate of $117.21 million, but showing a year-over-year decline of 1% [4] - Instruments revenue was reported at $14.5 million, below the average estimate of $14.9 million, marking a substantial year-over-year decrease of 39.2% [4] - Chromium instruments generated $5.73 million, slightly exceeding the estimated $5.6 million [4] - Services revenue amounted to $8.48 million, outperforming the estimate of $7.36 million, and reflecting a year-over-year increase of 43.9% [4] - Consumables from Chromium totaled $85.79 million, surpassing the estimate of $84.35 million [4] - Spatial consumables revenue was reported at $36.4 million, exceeding the average estimate of $32.86 million [4] - Spatial instruments revenue was $8.77 million, below the average estimate of $9.3 million [4] Stock Performance - Over the past month, shares of 10x Genomics have returned +4.6%, outperforming the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]